Literature DB >> 24507628

Synthesis and in vivo evaluation of N-ethylamino-2-oxo-1,2-dihydro-quinoline-3-carboxamide for inhibition of intestinal tumorigenesis in APC(Min/+) mice.

Gopal Pathuri1, Qian Li2, Altaf Mohammed2, Hariprasad Gali3, J Thomas Pento4, Chinthalapally V Rao2.   

Abstract

A selective KGFR tyrosine kinase inhibitor, N-ethylamino-2-oxo-1,2-dihydro-quinoline-3-carboxamide, was synthesized and its possible inhibitory effects on the development of colon polyps and colorectal tumors was examined in APC(Min/+) mice, a mouse model of human intestinal familial adenomatous polyposis. The present study shows for the first time that a dietary administration of a selective KGFR tyrosine kinase inhibitor lacks the overt-toxicities and significantly reduced the growth of small intestinal polyps in both male and female APC(Min/+) mice. This inhibition of polyp growth appears to occur at a greater extent in female mice.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemoprevention; Colon cancer; KFGR; Polyps; Tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2014        PMID: 24507628      PMCID: PMC3966088          DOI: 10.1016/j.bmcl.2014.01.042

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  14 in total

Review 1.  Perspectives on cancer chemoprevention research and drug development.

Authors:  G J Kelloff
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.

Authors:  Altaf Mohammed; Naveena B Janakiram; Qian Li; Chang-In Choi; Yuting Zhang; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-01

3.  Purification and characterization of a newly identified growth factor specific for epithelial cells.

Authors:  J S Rubin; H Osada; P W Finch; W G Taylor; S Rudikoff; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Characterization of the receptor for keratinocyte growth factor. Evidence for multiple fibroblast growth factor receptors.

Authors:  D P Bottaro; J S Rubin; D Ron; P W Finch; C Florio; S A Aaronson
Journal:  J Biol Chem       Date:  1990-08-05       Impact factor: 5.157

5.  Expression of keratinocyte growth factor and its receptor in colorectal cancer.

Authors:  J M Otte; F Schmitz; T Banasiewicz; M Drews; U R Fölsch; K H Herzig
Journal:  Eur J Clin Invest       Date:  2000-03       Impact factor: 4.686

6.  Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).

Authors:  M Oshima; J E Dinchuk; S L Kargman; H Oshima; B Hancock; E Kwong; J M Trzaskos; J F Evans; M M Taketo
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

7.  Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.

Authors:  Malisetty V Swamy; Jagan M R Patlolla; Vernon E Steele; Levy Kopelovich; Bandaru S Reddy; Chinthalapally V Rao
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

8.  Keratinocyte growth factor receptor expression in normal colorectal epithelial cells and differentiated type of colorectal cancer.

Authors:  Masanori Yoshino; Toshiyuki Ishiwata; Masanori Watanabe; Osamu Komine; Tetsuo Shibuya; Akira Tokunaga; Zenya Naito
Journal:  Oncol Rep       Date:  2005-02       Impact factor: 3.906

9.  Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.

Authors:  L K Su; K W Kinzler; B Vogelstein; A C Preisinger; A R Moser; C Luongo; K A Gould; W F Dove
Journal:  Science       Date:  1992-05-01       Impact factor: 47.728

Review 10.  Genetic alterations in the adenoma--carcinoma sequence.

Authors:  K R Cho; B Vogelstein
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.